Is OPCH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Acute infusion demand and hospital partnerships, with revenue (ttm) at ~$5.7B. The bear case rests on the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Analysts covering it are spread from $22.00 to $39.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $22.00, -8.8% from the $24.13 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Acute infusion demand and hospital partnerships. Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. The most optimistic analyst target on OPCH is $39.00, +61.6% from the $24.13 price. That figure is only reachable if this thesis works close to its best case.

The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure. The most pessimistic published target is $22.00, -8.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Acute infusion demand and hospital partnerships) stalling in the reported numbers rather than in the narrative, the risk above (the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It provides infusion therapy, delivering medications intravenously or by other infusion routes in patients' homes and at alternate-site suites. Its therapies span acute needs like post-hospital antibiotics and nutrition and chronic conditions such as immune, neurologic, and inflammatory diseases.

Yes. It generates positive net income (roughly $200 million on a trailing basis) and meaningful free cash flow, with FY2026 adjusted EBITDA guidance of about $480 to $505 million. Margins are thin because much of its revenue is drug pass-through cost.

Management cited a roughly 600 basis point headwind from its acute chronic-inflammatory-drug (CID) portfolio, including Stelara and biosimilar census resets and heavier benefit reverification work. Acute therapy is growing high single digits while chronic revenue has declined slightly.